Type
|
Public |
---|---|
Traded as | NASDAQ: HSIC NASDAQ-100 Component S&P 500 Component |
Industry | Health care supplies and services |
Founded | Queens, New York (1932 (1932)) |
Headquarters | Melville, New York, U.S. |
Key people
|
Stanley M. Bergman (Chairman and CEO) Jim Breslawski (President) Gerald A. Benjamin (Executive Vice President, CAO) |
Revenue | US $ 11.5 Billion (2016) |
Net income
|
US $ 506.7 Million (2016) |
Number of employees
|
Over 21,000 (2016) |
Website | http://www.henryschein.com |
Henry Schein Inc. is a distributor of health care products and services with a presence in 32 countries. The company is a Fortune World’s Most Admired Company and is ranked number one in its industry for social responsibility. Henry Schein has been recognized by the Ethisphere Institute as the World's Most Ethical Company five times as of 2016.
In 1932, Henry Schein, a graduate of Columbia University College of Pharmacy, borrowed $500 and opened a pharmacy in Queens, New York. The company expanded into dental supplies in the 1960s, and by the late 1980s, Henry Schein held approximately 10 percent of the dental-supply market. Marvin Schein, Henry Schein's son, took over management of daily operations in 1971.
In 1978, founder Henry Schein's son Jay Schein became CEO of the company. When Jay Schein died of cancer in 1989, Stanley Bergman took over as CEO.Bergman was born in South Africa and came to New York in 1976, where he became an accountant. In 1980, he joined Henry Schein and was promoted to CFO.
Henry Schein Inc. filed with the U.S. Securities and Exchange Commission in 1995 to sell 6.2 million shares in an initial public offering with William Blair & Company as the lead underwriter. The IPO raised $72.8 million and began trading on the Nasdaq. By 1996, the company was up to $1.4 billion in sales and $29 million in profit under Bergman's leadership. That year, the company made seventeen acquisitions.
In August 1997, Henry Schein Inc. agreed to buy Sullivan Dental Products Inc. for approximately $318 million. The purchase made the company the world's largest distributor of dental equipment and supplies. By that point, Henry Schein had made 16 acquisitions in 1997. Also in 1997, Henry Schein acquired New York-based medical-products distributor Micro BioMedics Inc as well as Dentrix Dental Systems.
Henry Schein announced the acquisition of demedis GmbH and Euro Dental Holding GmbH in June 2004. In November 2009, it was announced that Henry Schein Inc. and Butler Animal Health Supply would be launching joint venture Butler Schein Animal Health, the largest veterinary sales and distribution company in the United States. Butler Schein Animal Health was rebranded as Henry Schein Animal Health in 2013. Between 1989 and 2016, Henry Schein purchased approximately 200 companies. The company's chief executive officer, Stanley Bergman, was announced as Chief Executive Magazine's CEO of the Year in May 2017.
In 1997, Henry Schein acquired Sullivan Dental Products and Dentrix Dental Systems, making it the world's largest distributor of dental equipment and supplies. Dentrix Ascend, Henry Schein's cloud-based software designed for dental offices, is a scalable system. Its interface was built to be intuitive and the company works with users to include features dental offices require.
Henry Schein established the Henry Schein Dental Business Institute in March 2015 to teach owners and operators of dental practices the fundamentals of business. The first class to complete the program graduated in March 2016. Henry Schein also launched the Henry Schein Digital Dentistry Program at Temple University's Maurice H. Kornberg School of Dentistry in 2016.
In May 2016, Henry Schein's entity Dentrix presented the DEXIS software's ability to integrate X-rays into a patient's chart. Zahn Dental, Henry Schein's laboratory supply business, acquired Custom Automated Prosthetics in June 2016. The acquisition enabled Henry Schein to expand its prosthetic offerings.
In November 2014, Henry Schein Medical announced a strategic arrangement with Cardinal Health. Cardinal Health's physician office-sales organization consolidated into Henry Schein Medical.
Henry Schein Animal Health began in 1953 as the WA Butler Company in Columbus, Ohio as a local animal health distribution branch, and is the first distributor to set up regularly scheduled truck deliveries to veterinarians.
In 2002, WA Butler Company achieves sales of $400 million. We're recognized as the largest and most reliable distributor of animal health products in the United States.
In 2005, WA Butler Company merges with Burns Veterinary Supply to form Butler Animal Health Supply, LLC, owned and operated by Oak Hill Capital and Darby Group. Butler Animal Health Supply achieves sales of $785 million.
in 2010, Butler Animal Health Supply, LLC achieves sales of $1.2 billion. Henry Schein, Inc. acquires Butler Animal Health Supply, owning 50.1 percent and merges with NLS Animal Health to form Butler Schein Animal Health, LLC.
In 2013, Butler Schein Animal Health, LLC rebrands corporate identity as Henry Schein Animal Health.
In 2015, Henry Schein Animal Health acquires scil animal care company, USA in April of 2015. Based in Gurnee, Illinois, scil animal care is a specialized distributor which provides services and supports animal health laboratory diagnostic and imaging diagnostic solutions for veterinarians in the United States.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q4 2022 | 2023-02-16 | Future report Set alerts | |
Q3 2022 | 2022-11-01 | 1.09 | 1.09 |
Q2 2022 | 2022-08-02 | 1.16 | 1.16 |
Q1 2022 | 2022-05-03 | 1.30 | 1.30 |
Q4 2021 | 2022-02-15 | 1.07 | 1.07 |
Q3 2021 | 2021-11-02 | 1.10 | 1.10 |
Q2 2021 | 2021-08-03 | 1.11 | 1.11 |
Q1 2021 | 2021-05-04 | 1.24 | 1.24 |
Q4 2020 | 2021-02-17 | 1.00 | 1.00 |
Q3 2020 | 2020-11-02 | 1.03 | 1.03 |
2016-06-04 | Reiterated Rating | Credit Suisse | Hold | |
2016-06-04 | Reiterated Rating | Credit Suisse Group AG | Hold | |
2016-05-05 | Reiterated Rating | Leerink Swann | Hold | |
2016-05-04 | Reiterated Rating | Barrington Research | Outperform | $182.00 to $188.00 |
2016-03-16 | Boost Price Target | Robert W. Baird | $167.00 to $175.00 | |
2016-03-15 | Initiated Coverage | Credit Suisse | Neutral | $170.00 |
2016-03-01 | Upgrade | Barrington Research | Market Perform to Outperform | $182.00 |
2016-02-11 | Reiterated Rating | Piper Jaffray | Neutral | $158.00 to $159.00 |
2016-02-11 | Boost Price Target | Leerink Swann | Market Perform | $160.00 to $170.00 |
2016-02-11 | Boost Price Target | Goldman Sachs | Neutral | $149.00 to $154.00 |
2016-02-11 | Reiterated Rating | Piper Jaffray Cos. | Neutral | $158.00 to $159.00 |
2016-02-11 | Boost Price Target | Goldman Sachs Group Inc. | Neutral | $149.00 to $154.00 |
2015-12-03 | Reiterated Rating | Evercore ISI | Buy | $155.00 to $154.00 |
2015-11-06 | Downgrade | Gabelli | Buy to Hold | $6.60 to $5.90 |
2015-11-05 | Boost Price Target | RBC Capital | Outperform | $165.00 to $170.00 |
2015-11-05 | Boost Price Target | Leerink Swann | Market Perform | $150.00 to $160.00 |
2015-11-05 | Boost Price Target | Royal Bank Of Canada | Outperform | $165.00 to $170.00 |
2015-07-30 | Reiterated Rating | Evercore Partners Inc. | Buy to Hold | |
2015-07-30 | Downgrade | Evercore ISI | Buy to Hold | $159.00 to $157.00 |
2015-06-10 | Initiated Coverage | RBC Capital | Outperform | $165.00 |
2015-05-09 | Reiterated Rating | Robert W. Baird | Outperform | $151.00 to $153.00 |
2015-02-11 | Reiterated Rating | William Blair | Outperform | |
2014-11-07 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $114.00 to $131.00 |
2014-11-06 | Reiterated Rating | Credit Suisse | Neutral | $121.00 to $135.00 |
2014-10-13 | Upgrade | ISI Group | Neutral to Buy | $131 |
2014-10-13 | Upgrade | Evercore ISI | Neutral to Buy | $131.00 |
2014-08-05 | Reiterated Rating | Credit Suisse | Neutral | $120.00 to $121.00 |
2014-08-05 | Boost Price Target | Leerink Swann | Market Perform | $120.00 to $127.00 |
2014-08-04 | Lower Price Target | Evercore ISI | Neutral | $130.00 to $127.00 |
2014-03-10 | Upgrade | Ned Davis Research | Neutral to Buy | |
2014-02-12 | Boost Price Target | Piper Jaffray | $113.00 to $118.00 | |
2013-10-14 | Boost Price Target | Evercore ISI | Neutral | $106.00 to $110.00 |
2013-09-30 | Downgrade | Ned Davis Research | Buy to Neutral | |
2013-04-15 | Reiterated | ISI Group | Neutral | $88 to $94 |
2013-02-13 | Reiterated | ISI Group | Neutral | $84 to $88 |
2012-04-10 | Initiated | Auriga | Hold | $73 |
2011-12-06 | Initiated | Deutsche Bank | Hold | $66.50 |
2011-05-16 | Reiterated | Barclays Capital | Equal Weight | $75 to $78 |
2011-05-03 | Reiterated | Barrington Research | Outperform | $74 to $80 |
2010-09-02 | Reiterated | UBS | Neutral | $62 to $60 |
2010-06-15 | Reiterated | UBS | Neutral | $69 to $62 |
2010-04-16 | Initiated | Susquehanna Financial | Positive | |
2010-04-14 | Upgrade | Barrington Research | Mkt Perform to Outperform | $74 |
2010-03-09 | Initiated | UBS | Neutral | $63 |
2016-06-04 | Reiterated Rating | Credit Suisse | Hold | |
2016-06-04 | Reiterated Rating | Credit Suisse Group AG | Hold | |
2016-05-05 | Reiterated Rating | Leerink Swann | Hold | |
2016-05-04 | Reiterated Rating | Barrington Research | Outperform | $182.00 to $188.00 |
2016-03-16 | Boost Price Target | Robert W. Baird | $167.00 to $175.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In HSIC 427 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 15.62M |
GENERATION INVESTMENT MANAGEMENT LLP | 12.89M |
BlackRock Inc. | 10.59M |
Longview Partners (Guernsey) LTD | 7.10M |
STATE STREET CORP | 6.94M |
Invesco Ltd. | 5.28M |
AMERICAN CENTURY COMPANIES INC | 4.57M |
JPMORGAN CHASE & CO | 3.33M |
GEODE CAPITAL MANAGEMENT, LLC | 3.19M |
MACQUARIE GROUP LTD | 2.43M |
BlackRock Institutional Trust Company, N.A. | 2.29M |
BlackRock Fund Advisors | 1.95M |
FIDUCIARY MANAGEMENT INC /WI/ | 1.91M |
Burgundy Asset Management Ltd. | 1.74M |
Swedbank | 1.59M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
BERGMAN STANLEY M Chairman, CEO | 0.28% (240916) | HSIC / |
BRESLAWSKI JAMES P Pres., HSI & CEO Global Dental | 0.26% (223314) | HSIC / |
PALADINO STEVEN EVP, Chief Financial Officer | 0.21% (175414) | HSIC / MSM / |
BENJAMIN GERALD A EVP, Chief Admin. Officer | 0.12% (100820) | HSIC / |
MLOTEK MARK E EVP, Chief Strategic Officer | 0.11% (89865) | HSIC / |
McKinley David President, Medical Group | 0.09% (76333) | HSIC / |
Ettinger Michael S SVP, Corp & Legal Affairs, Sec | 0.09% (72268) | HSIC / |
Prange Karen EVP&CEO Gl.AH.Med.Den.Sur.Grp | 0.07% (62902) | BSX / HSIC / |
ALPERIN BARRY J | 0.05% (43807) | FRGI / HAIN / HSIC / |
Siegel Walter Senior VP & General Counsel | 0.04% (37992) | HSIC / |
SHEARES BRADLEY T | 0.04% (33693) | CVD / HON / HSIC / PGR / |
McGlynn Lorelei SVP, Global HR & Fin. Oper. | 0.04% (33048) | HSIC / |
Shoff Lonnie Pres. & CEO, Global AH & SP | 0.04% (31000) | HSIC / |
LASKAWY PHILIP A | 0.03% (27942) | HSIC / L / LAZ / |
KOMAROFF STANLEY Senior Advisor | 0.03% (25144) | HSIC / |
RACIOPPI MICHAEL SVP Chief Merchandising Offic. | 0.03% (23088) | HSIC / |
Minowitz Robert President, Int\'l Dental Group | 0.03% (22943) | HSIC / |
Brons Paul | 0.03% (22489) | HSIC / |
MASHIMA Karyn | 0.02% (19269) | HSIC / |
Raphael Carol | 0.02% (18747) | HSIC / |
Rose Paul SVP, Global Supply Chain | 0.02% (17841) | HSIC / |
Harding James A. Chief Technology Officer | 0.02% (16589) | HSIC / |
MATTHEWS NORMAN S | 0.02% (15425) | HSIC / PLCE / SPB / |
McCarthy Peter M. Pres., Global Animal Health | 0.02% (14277) | HSIC / |
SULLIVAN LOUIS W | 0.02% (14096) | EBS / HSIC / UTHR / |
Rekow E Dianne | 0.02% (13391) | HSIC / |
DAVID LEONARD A Senior Vice President, CCO | 0.01% (12343) | HSIC / |
KABAT DONALD J | 0.01% (10874) | HSIC / |
BACOW LAWRENCE S | 0.01% (10115) | HSIC / L / |
Ross Bridget A President, Global Medical Grp | 0.01% (9654) | HSIC / |
KUEHN KURT P | 0.01% (9089) | HSIC / NCR / UPS / |
HERRING JOSEPH L | 0.01% (7089) | CVD / HSIC / LH / TMH / |